We are thrilled to announce Shawn M. Leland, Pharm D, RPh is @affimed's new CEO. Shawn has a proven track record in advancing cutting-edge oncology assets, securing significant capital, and negotiating global licensing agreements. Read more here: bit.ly/3Tdpv2k #AFMD

Today @affimed announced that it has received FDA Fast Track Designation for AFM13 combined w/ AB-101 for the treatment of patients with R/R Hodgkin lymphoma which will be investigated in the LuminICE-203 study (NCT05883449). Press release: bit.ly/3PfDqlB #Affimed

Today at 8:30 a.m. EDT / 14:30 CET, we discuss our Q2 2023 results and corporate update in a conference call. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at bit.ly/3Qz1x0V #AFMD

Today Affimed provided details on the AFM24-101 monotherapy study in NSCLC at ASCO 2023 and provides a strategic update on the AFM24 development plan. For further details, see the full press release at: bit.ly/3WQ1bUX. #AFMD #AFM24 #ImmunoOncology

@Affimed will be hosting an investor event June 3, 2023, at 6:00 PM CDT/ 7:00 PM EDT to review AFM24 monotherapy data and provide a strategic update on the program going forward. Webcast: bit.ly/43ACvls Dial in: bit.ly/45GHN0s #AFMD #AFM24 #InnateImmunity

Affimed is pleased to announce two abstracts at EHA2023, the Annual Meeting of the European Hematology Association. Read more here bitly.ws/EpkQ #immunooncology #AFM13 #AFM28 #EHA2023

We are pleased to announce that we have dosed the first patient in our first-in-human study investigating AFM28 in patients with relapsed/refractory CD123-positive Acute Myeloid Leukemia (AML). Read the full press release here: bitly.ws/CgZS

Today at 8:30 a.m. EDT / 13:30 CET, we discuss our full year 2022 results and corporate update in a conference call. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website. Full PR: bitly.ws/BYQN

Join us at this year’s Annual Meeting of the @AACR in Orlando, Florida! We will host an oral presentation on results from our REDIRECT study and a poster presentation on the potential of AFM13 to induce effective ADCC. To the PR: bit.ly/3la19c6 #ImmunoOncology

Our CEO, Adi Hoess will participate in a fireside chat at the @HCWCO Cell Therapy Conference today. Join our webcast bit.ly/3IINTEe at 8:30 a.m. EST / 14:30 CET to learn more about Affimed’s approach to fighting cancer.

Thank you @Cormac_Sheridan for taking the time to speak with our CMO, Dr. Andreas Harstrick, about Affimed's exciting data and the synergistic potential that ICE® molecules bring to the NK cell space. Read the article in Nature Biotechnology here: go.nature.com/3k7vNSD

Join our CEO Adi Hoess for a fireside chat with Daina Greybosch, Ph.D., at this year's SVB Securities 2023 Global Biopharma Conference at 2:20 p.m. EST / 8:20 p.m. CET on Tuesday, February 14, 2023. To the webcast: bit.ly/3K3dAAl

Today we announced a regulatory update for #AFM13 & reported on corporate progress. Read more here bit.ly/3VSCaWR. #AFM13 #InnateImmunity #ImmunoOncology

The French National Agency for the Safety of Medicines & Health Products has authorized a CTA for our innate cell engager (ICE®), #AFM28. This allows us to advance its clinical development to fight relapsed / refractory #AML, a severe blood cancer: bit.ly/3WuVsTa

Today at #ASH22 we gave an update on our preclinical innate cell engager (ICE®) #AFM28, targeting CD123+ cells in diseases such as acute myeloid #leukemia. AFM28 can successfully destroy tumor cells! bit.ly/3VOLXhC #WhyWeFightCancer #AffimedProud #AFM13 #InnateImmunity

Today, we announced 2 important data sets: topline data from our monotherapy Phase 2 REDIRECT trial in r/r PTCL patients & data from our study with @MDAndersonNews evaluating the combination of AFM13 with NK cells. More here:bit.ly/3haDXZf bit.ly/3PicLEf #ASH22

Affimed will be hosting an investor event on December 10th at 4 p.m. CST / 5 p.m. EST / 23:00 CET in conjunction with #ASH22 to provide an update on our AFM13 development strategy. Please find more information here: bit.ly/3XQ8snC

Our CEO, Adi Hoess will be giving a talk at this year’s @Jefferies Healthcare Conference in London. Join his presentation via our webcast bit.ly/3O1EyIG on Wednesday, November 16th, 2022, at 7:55 EST/ 13:55 CET. #JefferiesHealthcare

Today, we announce our Q3 2022 financial results and provide a corporate update. Access our Investor's call at 8:30 a.m. EST / 14:30 CET with the following link: bit.ly/3g7AoCy - A replay will be available for 30 days. To the press release: bit.ly/3hC2u9b

Listen to our CSO, Arndt Schottelius giving a talk #PEGSEurope on the early clinical outcomes of the AFM13-NK cell combination trial on Nov 15th, at 9:30 CET in Barcelona. Find the agenda here bit.ly/3DexHqo or learn about our recent update here: bit.ly/3tu2ye0